B J Guglielmo

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc Pharmacokinetics of quinacrine in the treatment of prion disease
    Lotus Yung
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143 0622, USA
    BMC Infect Dis 4:53. 2004
  2. pmc Prevention of adverse events in hospitalized patients using an antimicrobial review program
    B J Guglielmo
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco 94143 0622, USA
    West J Med 171:159-62. 1999
  3. ncbi request reprint Ceftriaxone therapy for staphylococcal osteomyelitis: a review
    B J Guglielmo
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143 0622, USA
    Clin Infect Dis 30:205-7. 2000
  4. ncbi request reprint Impact of a series of interventions in vancomycin prescribing on use and prevalence of vancomycin-resistant enterococci
    B Joseph Guglielmo
    Department of Clinical Pharmacy, University of California San Francisco, USA
    Jt Comm J Qual Patient Saf 31:469-75. 2005
  5. doi request reprint Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation
    T Martin
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California, USA
    Transpl Infect Dis 12:45-50. 2010
  6. ncbi request reprint Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals
    V Dudas
    University of California, San Francisco 94143, USA
    Ann Pharmacother 34:446-52. 2000
  7. ncbi request reprint Impact of an intravenous fluconazole restriction policy on patient outcomes
    J S Burkiewicz
    School of Pharmacy, University of California, San Francisco, CA, USA
    Ann Pharmacother 35:9-13. 2001
  8. pmc Patient education for H pylori: who benefits?
    Katherine Yang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco 521 Parnassus Ave, Room C 152 San Francisco, CA 94143 0622, USA
    West J Med 176:97. 2002
  9. ncbi request reprint In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4
    Jean Paul A Nicandro
    Dept of Clinical Pharmacy, University of California, San Francisco, CA 94143, USA
    J Herb Pharmacother 7:39-56. 2007
  10. pmc Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms
    Katherine Yang
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, San Francisco, CA 94143, USA
    Ann Pharmacother 41:1427-35. 2007

Collaborators

  • J F Flaherty
  • T Martin
  • V Dudas
  • L Z Benet
  • Dimple Patel
  • Katherine Yang
  • Conan MacDougall
  • Peter M Houck
  • Ralph Gonzales
  • Helen Kim
  • Michael T Lawton
  • Dale W Bratzler
  • Yong Huang
  • Chanhung Z Lee
  • Emil T Lin
  • Tim Frenzel
  • Brian S Schwartz
  • Charles E McCulloch
  • Jean Paul A Nicandro
  • William L Young
  • Marisa N Mendez
  • Daniel H Deck
  • Stanley B Prusiner
  • Giuseppe Legname
  • Nancy N Chang
  • Amy N Bower
  • Richard A Jacobs
  • Lotus Yung
  • Karla M Killgore
  • David E Hickman
  • Dana D Phan
  • Larissa R Graff
  • J S Burkiewicz
  • Penny D Ngo
  • Tomoki Hashimoto
  • Nancy J Quinnine
  • Lynda Frassetto
  • Candy Tsourounis
  • Laurel Gibbs
  • Jianhua S Yao
  • Lisa Winston
  • Wenwu Zhai
  • Hideaki Okochi
  • Emil Lin
  • Weizhong Liu
  • Guo Yuan Yang
  • Barnaby C H May
  • Cynthia K Murray
  • Claudette Greenway
  • Helena M Tang
  • Pierre Lessard
  • Michael Baldwin
  • Chongsuk Ryou
  • Kristi L March
  • Peter Chin-Hong
  • Pascale Anderle
  • Wolfgang Sadee
  • John R Hanak
  • Marilyn R Stebbins
  • Lana Witt
  • Lucy Tompkins
  • Neal Cohen
  • Kristal K Franklin
  • R A Jacobs
  • K A Kostiuk

Detail Information

Publications24

  1. pmc Pharmacokinetics of quinacrine in the treatment of prion disease
    Lotus Yung
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143 0622, USA
    BMC Infect Dis 4:53. 2004
    ..If quinacrine penetrates brain tissue in concentrations exceeding that demonstrated for in vitro inhibition of PrPSc, it may be useful in the treatment of prion disease...
  2. pmc Prevention of adverse events in hospitalized patients using an antimicrobial review program
    B J Guglielmo
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco 94143 0622, USA
    West J Med 171:159-62. 1999
    ..To evaluate whether an antimicrobial review system is associated with a reduction in antimicrobial-associated adverse events...
  3. ncbi request reprint Ceftriaxone therapy for staphylococcal osteomyelitis: a review
    B J Guglielmo
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, CA 94143 0622, USA
    Clin Infect Dis 30:205-7. 2000
    ..It is concluded that ceftriaxone is effective in the ambulatory treatment of S. aureus osteomyelitis...
  4. ncbi request reprint Impact of a series of interventions in vancomycin prescribing on use and prevalence of vancomycin-resistant enterococci
    B Joseph Guglielmo
    Department of Clinical Pharmacy, University of California San Francisco, USA
    Jt Comm J Qual Patient Saf 31:469-75. 2005
    ..In response to vancomycin-resistant bacteria, particularly vancomycin-resistant enterococci (VRE), measures have been recommended to improve on the appropriate use of vancomycin...
  5. doi request reprint Voriconazole is safe and effective as prophylaxis for early and late fungal infections following allogeneic hematopoietic stem cell transplantation
    T Martin
    Division of Hematology Oncology, University of California San Francisco, San Francisco, California, USA
    Transpl Infect Dis 12:45-50. 2010
    ..No Candida infections were seen in either period. These data suggest that fungal prophylaxis with VOR following allogeneic transplantation is safe and effective...
  6. ncbi request reprint Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals
    V Dudas
    University of California, San Francisco 94143, USA
    Ann Pharmacother 34:446-52. 2000
    ..Secondary outcomes included length of stay (LOS) and mortality associated with the choice of therapy...
  7. ncbi request reprint Impact of an intravenous fluconazole restriction policy on patient outcomes
    J S Burkiewicz
    School of Pharmacy, University of California, San Francisco, CA, USA
    Ann Pharmacother 35:9-13. 2001
    ..To evaluate both the economic and clinical impact of an intravenous fluconazole restriction policy in a university teaching hospital...
  8. pmc Patient education for H pylori: who benefits?
    Katherine Yang
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco 521 Parnassus Ave, Room C 152 San Francisco, CA 94143 0622, USA
    West J Med 176:97. 2002
  9. ncbi request reprint In vivo effect of I'm-Yunity on hepatic cytochrome P450 3A4
    Jean Paul A Nicandro
    Dept of Clinical Pharmacy, University of California, San Francisco, CA 94143, USA
    J Herb Pharmacother 7:39-56. 2007
    ..However, it is still unknown whether interactions exist between I'm-Yunity and other medications metabolized by other CYP450 isozymes or enzyme/transporter systems...
  10. pmc Diagnosis and treatment of extended-spectrum and AmpC beta-lactamase-producing organisms
    Katherine Yang
    Department of Clinical Pharmacy, School of Pharmacy, University of California at San Francisco, San Francisco, CA 94143, USA
    Ann Pharmacother 41:1427-35. 2007
    ..To review the laboratory diagnosis of extended-spectrum beta-lactamase (ESBL) and AmpC beta-lactamase-producing bacteria and evaluate potential treatment options...
  11. doi request reprint Antimicrobial stewardship programs: interventions and associated outcomes
    Dimple Patel
    University of California, San Francisco School of Pharmacy, 521 Parnassus Avenue, C 152, San Francisco, CA 94143, USA
    Expert Rev Anti Infect Ther 6:209-22. 2008
    ..Antimicrobial stewardship programs are becoming increasingly associated with clear benefits and will be integral in the in-patient healthcare setting...
  12. ncbi request reprint Impact of a piperacillin-tazobactam shortage on antimicrobial prescribing and the rate of vancomycin-resistant enterococci and Clostridium difficile infections
    Marisa N Mendez
    Department of Clinical Pharmacy, School of Pharmacy, School of Medicine, University of California San Francisco, San Francisco, California 94143, USA
    Pharmacotherapy 26:61-7. 2006
    ..difficile infections.Conclusion: The piperacillin-tazobactam shortage was associated with significant changes in antimicrobial prescribing, which resulted in a significant reduction in the rate of C. difficile but not VRE infections...
  13. ncbi request reprint Daptomycin treatment failure for vancomycin-resistant Enterococcus faecium infective endocarditis: impact of protein binding?
    Brian S Schwartz
    Ann Pharmacother 42:289-90. 2008
  14. ncbi request reprint Quinacrine is mainly metabolized to mono-desethyl quinacrine by CYP3A4/5 and its brain accumulation is limited by P-glycoprotein
    Yong Huang
    Department of Biopharmaceutical Sciences, School of Pharmacy, University of California San Francisco, CA 94143 0446, USA
    Drug Metab Dispos 34:1136-44. 2006
    ..v. dose and <2 times greater after 10 mg/kg oral doses in MDR1-KO mice compared with WT mice. These results indicate that P-gp plays a critical role in transporting QA from the brain...
  15. pmc Feasibility of minocycline and doxycycline use as potential vasculostatic therapy for brain vascular malformations: pilot study of adverse events and tolerance
    Tim Frenzel
    Center for Cerebrovascular Research, Department of Anesthesia and Perioperative Care, University of California, San Francisco, CA 94110, USA
    Cerebrovasc Dis 25:157-63. 2008
    ..Tetracyclines may be useful in preventing pathological vascular remodeling, thus decreasing the risk of spontaneous hemorrhage from brain vascular malformations...
  16. ncbi request reprint Pharmacological advances in the treatment of invasive candidiasis
    Daniel H Deck
    San Francisco General Hospital, San Francisco, CA, USA
    Expert Rev Anti Infect Ther 4:137-49. 2006
    ..The availability of new agents, future adoption of diagnostic tests for candidiasis, and susceptibility testing will have a major impact in the management of invasive candidiasis...
  17. ncbi request reprint Dose-response effect of tetracyclines on cerebral matrix metalloproteinase-9 after vascular endothelial growth factor hyperstimulation
    Chanhung Z Lee
    Department of Anesthesia and Perioperative Care, University of California, San Francisco, 94110, USA
    J Cereb Blood Flow Metab 26:1157-64. 2006
    ..This study provided the evidence that the tetracyclines inhibit stimulated cerebral MMP-9 at multiple levels and are effective at very low doses, offering great potential for therapeutic use...
  18. pmc Antimicrobial drug prescribing for pneumonia in ambulatory care
    Conan MacDougall
    University of California School of Pharmacy, San Francisco, California, USA
    Emerg Infect Dis 11:380-4. 2005
    ..Clear and consistent guidelines are needed to address the role of fluoroquinolones in treatment of outpatient community-acquired pneumonia...
  19. ncbi request reprint Antimicrobial therapy of gram-negative bacteremia at two university-affiliated medical centers
    Larissa R Graff
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, California 94143, USA
    Am J Med 112:204-11. 2002
    ..To describe antimicrobial prescribing practices and patient outcomes associated with the treatment of aerobic gram-negative rod bacteremia at two university-affiliated medical centers...
  20. ncbi request reprint Compliance in two medical centers with criteria for use of caspofungin and lipid-based amphotericin B
    Amy N Bower
    School of Pharmacy, University of California at San Francisco, 94143 0622, USA
    Am J Health Syst Pharm 61:915-20. 2004
    ..Patterns of use and compliance with guidelines for use of lipid-based amphotericin B (LBA) and caspofungin at two medical institutions were studied...
  21. ncbi request reprint Risk factors for community-acquired ciprofloxacin-resistant Escherichia coli urinary tract infection
    Karla M Killgore
    Department of Clinical Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Ann Pharmacother 38:1148-52. 2004
    ..Identification of outpatients at increased risk for fluoroquinolone resistance would improve the selection of empiric treatment...
  22. pmc Intra- and interindividual variabilities of valacyclovir oral bioavailability and effect of coadministration of an hPEPT1 inhibitor
    Dana D Phan
    School of Pharmacy, University of California, San Francisco, California 94143, USA
    Antimicrob Agents Chemother 47:2351-3. 2003
    ..These results suggest a stable valacyclovir absorption phenotype, significant interindividual variability, and minimal interaction between these hPEPT1 substrates...
  23. ncbi request reprint Pharmacy-based intervention to reduce antibiotic use for acute bronchitis
    David E Hickman
    Department of Clinical Pharmacy, School of Pharmacy, University of California, San Francisco, CA 94143 0622, USA
    Ann Pharmacother 37:187-91. 2003
    ..Intervention programs can reduce inappropriate antibiotic use for the treatment of acute bronchitis in a closed health maintenance organization model...
  24. ncbi request reprint Blood culture and susceptibility results and allergy history do not influence fluoroquinolone use in the treatment of community-acquired pneumonia
    Nancy N Chang
    Department of Clinical Pharmacy, School of Pharmacy, University of California San Francisco, San Francisco, California 94143, USA
    Pharmacotherapy 25:59-66. 2005
    ..To determine the influence of blood culture and susceptibility results and antimicrobial allergy history on fluoroquinolone use in the treatment of community-acquired pneumonia...